Literature DB >> 26045506

Non-vitamin K antagonist oral anticoagulants (NOAC): considerations on once- vs. twice-daily regimens and their potential impact on medication adherence.

Hein Heidbuchel1, Bernard Vrijens2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26045506     DOI： 10.1093/europace/euv124

Source DB:  PubMed          Journal:  Europace        ISSN： 1099-5129            Impact factor:   5.214


× No keyword cloud information.
  5 in total

1.  Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients.

Authors:  Morten Lamberts; Laila Staerk; Jonas Bjerring Olesen; Emil Loldrup Fosbøl; Morten Lock Hansen; Louise Harboe; Cinira Lefevre; David Evans; Gunnar Hilmar Gislason
Journal:  J Am Heart Assoc       Date:  2017-02-14       Impact factor: 5.501

2.  Clinical presentation, diagnostic findings and management of cerebral ischemic events in patients on treatment with non-vitamin K antagonist oral anticoagulants - A systematic review.

Authors:  Thomas Raphael Meinel; Sebastién Frey; Marcel Arnold; Sarah Kendroud; Urs Fischer; Johannes Kaesmacher; Mirjam Rachel Heldner; Simon Jung
Journal:  PLoS One       Date:  2019-03-29       Impact factor: 3.240

3.  Adherence with direct oral anticoagulants in patients with atrial fibrillation: Trends, risk factors, and outcomes.

Authors:  Anat Arbel; Zomoroda Abu-Ful; Meir Preis; Shai Cohen; Walid Saliba
Journal:  J Arrhythm       Date:  2021-11-18

4.  Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary.

Authors:  Hein Heidbuchel; Peter Verhamme; Marco Alings; Matthias Antz; Hans-Christoph Diener; Werner Hacke; Jonas Oldgren; Peter Sinnaeve; A John Camm; Paulus Kirchhof
Journal:  Eur Heart J       Date:  2017-07-14       Impact factor: 29.983

5.  Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries.

Authors:  Joris J Komen; Anton Pottegård; Aukje K Mantel-Teeuwisse; Tomas Forslund; Paul Hjemdahl; Björn Wettermark; Maja Hellfritzsch; Jesper Hallas; Morten Olesen; Marion Bennie; Tanja Mueller; Annemarie Voss; Tania Schink; Ulrike Haug; Bianca Kollhorst; Øystein Karlstad; Lars J Kjerpeseth; Olaf H Klungel
Journal:  Europace       Date:  2021-11-08       Impact factor: 5.214
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.